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Abstract
Introduction
At present, information about clinical efficacy and adverse events of controlled release (CR)
form of pelubiprofen, a prodrug of 2-arylopropionic acid with relatively selective effects on
cyclooxygenase-2 activity, remains scarce. In this study, we sought to determine non-inferi-
ority of pelubiprofen CR 90 mg/day compared to aceclofenac 200 mg/day regarding clinical
efficacy and adverse events after a 4-week course of medication in the patients with symp-
tomatic knee osteoarthritis.
Materials and methods
A total of 191 patients were randomly assigned to take either pelubiprofen CR 90 mg (n =
95) or aceclofenac 200 mg (n = 96). The primary outcome variable was non-inferiority of
pain reduction between baseline and week 4 when assessed using a 100 mm pain visual
analogue scale (VAS). Pelubiprofen was considered non-inferior to aceclofenac if the upper
limit of the one-sided 97.5% confidence interval for the difference in terms of pain VAS was
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above 15 mm (the average change of pain VAS in the pelubiprofen group-pain VAS reduc-
tion in the aceclofenac group). Secondary outcome variables were the changes in 100 mm
pain VAS at week 2 versus baseline, K-Western Ontario, and McMaster University Arthritis
Index (K-WOMAC) changes at weeks 2 and 4 as compared to baseline, patient global
assessment at weeks 2 and 4. The frequency and amount of rescue medicine usage at
weeks 2 and 4 were also evaluated as the secondary outcome variable. For safety analysis,
adverse events, clinical laboratory tests, vital signs, and physical examinations were
assessed and conducted at each follow-up visit.
Results
At week 4, the pain VAS values were significantly reduced in both groups receiving either
pelubiprofen CR 90 mg or aceclofenac 200 mg as compared to the baseline. However, the
pelubiprofen group and the aceclofenac group respectively showed the pain VAS changes
of -22 and -21.9 in the pre-protocol set and -20.8 and -21.7 in the full analysis set, confirming
non-inferiority. The pelubiprofen CR 90 mg showed a reduced incidence of adverse events
compared to the aceclofenac 200 mg (p = 0.005).
Conclusions
Pelubiprofen CR 90 mg is as effective as aceclofenac 200 mg with reduced adverse events
for the treatment of symptomatic knee osteoarthritis.
Introduction
Osteoarthritis (OA), one of the most common chronic diseases, causes symptoms such as pain
and disability of joints in the elderly [1–3]. Patients with knee OA typically use medication to
reduce the symptoms, although some patients with the end-stage OA require surgical treatment
[4, 5]. Patients usually use non-steroidal anti-inflammatory drugs (NSAIDs) in the long-term, as
NSAIDs do not alter the natural course of the knee OA [6, 7]. However, the long-term use of
NSAIDs frequently causes adverse events (AEs) such as dyspepsia, abdominal pain, gastric ulcers,
and renal damage [8]. Therefore, given that the patients with knee OA are typically elderly and
thus have multiple comorbidities, both safety and efficacy of the NSAIDs are of essence.
Pelubiprofen, one of the 2-arylpropionic acid drugs, is structurally and pharmacologically
related to ibuprofen [9]. Previously, it was reported that pelubiprofen has selective inhibitory
effects on COX-2 activity [10]. In the study of the patients with rheumatoid arthritis (RA),
pelubiprofen 90 mg showed non-inferiority to celecoxib 200 mg in terms of visual analogue
scale (VAS) pain severity and AEs [9]. Furthermore, pelubiprofen 90 mg was not inferior to
aceclofenac 200mg in terms of the degree of pain relief in the patients with chronic lower back
pain [11]. Therefore, it can reasonably be predicted that pelubiprofen 90 mg would also have
similar effect on the patients with knee OA without increase of AEs. However, previous
research findings on the effect of controlled release (CR) from of pelubiprofen in the patients
with knee OA remain scarce.
Among commonly used NSAIDs, aceclofenac is a phenylacetic acid derivative which is
structurally related to diclofenac that showed a higher therapeutic index than other NSAIDs
with similar analgesic activity [7, 12]. Furthermore, in a recent meta-analysis, aceclofenac was
reported to have benefits over control analgesics in terms of function improvement. In this
previous meta-analysis, aceclofenac showed benefits compared to diclofenac, and the
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difference between the two drugs corresponded to a difference in pain score of 1.15 cm on a
10-cm VAS scale [7]. In addition, aceclofenac showed reduced gastrointestinal (GI) AEs com-
pared to other traditional NSAIDs [7].
Therefore, in the present study, we sought to evaluate non-inferiority of pelubiprofen CR
90 mg compared to aceclofenac 200 mg regarding clinical efficacy and AEs after a 4-week
course of medication in the patients with symptomatic knee OA.
Materials and methods
Study participants
The patients visited from August 2015 to March 2016 and aged from 35 to 80 years old with
symptomatic, primary knee OA were included in this prospective randomized controlled trial.
Inclusion criteria were as follows: 1) diagnosis with knee OA according to the American Col-
lege of Rheumatology (ACR) guidelines; 2) the Kellgren-Lawrens (K-L) grade I-III OA on
knee radiographs; 3) stable knee pain for at least 3 months; 4) pain on a visual analogue scale
(VAS) score of� 40 mm after the NSAIDs/analgesic washout. This study included both
femorotibial knee OA and patellofemoral knee OA patients. K-L grading was performed on
the worse grading of the two compartments. Prospective participants were excluded if they
had secondary OA, inflammatory arthritis such as RA, a history of surgery (including artificial
knee joint surgery) and/or trauma in the knee joint within the previous 12 months, as well as
had conditions that could confound the assessment of efficacy of the tested drug, such as tendi-
nitis, bursitis, and fibromyalgia of the lower extremities. Furthermore, the patients with the fol-
lowing conditions were also excluded: a history of opioid use for over 3 months, intra-articular
corticosteroid injection or systemic corticosteroid use (> 1500 μg) within the previous 3
months, intra-articular hyaluronic acid injection within previous 2 months, gastric ulcer or
gastritis confirmed using endoscopy, genetic galactose intolerance, lactase deficiency or glu-
cose-galactose uptake, contraindication for use of NSAID (such as allergic reactions), need of
pain treatment regarding pre- or post-coronary artery bypass graft (CABG), active malig-
nancy, ulcerative colitis, Crohn’s disease, active renal and/or liver diseases, significant hemato-
logic, cardiac, pulmonary diseases, uncontrolled hypertension (systolic pressure� 160 mmHg
and/or diastolic pressure� 100 mmHg), and substance dependence (alcohol or other drugs).
Women of childbearing age who did not agree to use an effective method of birth control, had
positive serum pregnancy results, and were lactating were also excluded. All participants
signed written consent forms before participating in this clinical study.
Sample size calculation
Power analysis of the designed trial showed that a sample size of 85 patients per group would
be needed. To calculate sample size required to evaluate non-inferiority between pelubiprofen
CR 90 mg and aceclofenac 200 mg for clinical efficacy, the following conditions were used: sta-
tistical power, 1-ß = 0.975; level of significance, a one-sided α = 0.025. We set the non-inferior-
ity margin of the difference between pelubiprofen CR 90 mg and aceclofenac 200 mg to 15
mm of the VAS score ranging from 0 to 100 mm [13]. The sample size for each group required
for a confidence interval of 95% and power of 97.5% was calculated using the following for-
mula:
nt ¼
ðs2t þ s
2
c ÞðZ1  a þ Z1  bÞ
2
d
2
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In a previous study that compared aceclofenac and paracetamol in the management of
symptomatic OA of the knee, the range of changes in 100 mm pain VAS score in the aceclofe-
nac group was -18.34 ± 24.86 mm [14]. Therefore, for our sample size calculation, we set the
standard deviation of 24.86. With these assumptions and estimating a dropout rate of 10%, the
final sample size of 95 patients per group was obtained.
Study design
The study was performed in the patients with knee osteoarthritis for 7 months as a multi-cen-
ter, randomized, double-blinded, parallel-group, phase IV, and non-inferiority study.
Researchers from 10 centers participated in this study from August 2015 to March 2016. All
study protocols were approved by the institutional review boards of each hospital
(DW_PlbCR_401) (SMG-SNU Boramae Medical Center, Inha University Hospital, Kyung
Hee University Hospital at Gangdong, Dankook University Hospital, Seoul National Univer-
sity Hospital, Gangnam Severance Hospital, Korea University Medical Center, Chung-Ang
University Hospital, Samsung Medical Center, and Ewha University Medical Center). This
trial was registered with clinicalTrial.gov (NCT02682524). The patients were randomly
assigned to one of the two study groups (pelubiprofen CR 90 mg or aceclofenac 200 mg) at the
ratio of 1:1. Before the clinical trial, the randomization table (a sequential application of ran-
dom numbers generated by the randomization program of SAS 9.2v system (SAS Institute,
Cary, NC) starting from subject number 1) was generated by a statistician. The patients in the
pelubiprofen group received pelubiprofen 90 mg (one 45 mg tablet, twice a day) for 4 weeks
with an aceclofenac placebo tablet in the morning and evening. The patients in the aceclofenac
group received 200 mg of aceclofenac (one 100 mg tablet, twice a day) for 4 weeks with a pelu-
biprofen placebo tablet in the morning and evening. Acetaminophen was used as the rescue
medicine, and the patients were allowed to take one Tylenol ER sustained release tablet (acet-
aminophen 650 mg) as needed (but up to 3 tablets per day).
Fourteen days prior to the randomized assignment, the patients who had previously
received NSAIDs, osteoarthritis nutrition, physiotherapy, and oriental medicine remedies had
a drug wash-out period, which involved discontinuation of the administration and application
of those drugs and therapies. The investigators maintained the double blind and performed
the examination; the release of the double blind was considered on a case-by-case basis only in
the event of a serious medical emergency, and the double blind was released when the infor-
mation on the administration group affected the treatment of the patients.
Efficacy and safety assessments
After the random assignment, follow-up visits were conducted on the days of baseline (week
0), and at weeks 2 and 4 after the drug administration. At the screening visit, we checked vital
signs/weight and performed physical examinations, laboratory tests (complete blood count,
electrolytes, blood urea nitrogen (BUN), creatinine, uric acid, total bilirubin, albumin, pro-
thrombin time (PT), activated partial thromboplastin time (aPTT), urine human chorionic
gonadotropin (hCG), urine protein, urine glucose), electrocardiogram (ECG), conventional
radiographs and measured 100 mm pain VAS. At the baseline visit, we checked vital signs, per-
formed weight measurements and physical examinations, and measured 100 mm pain VAS
and K-WOMAC [15]. During the visit at 2 weeks after the administration, we checked vital
signs, pain VAS, K-WOMAC, and did global patient assessment. During the visit at 4 weeks
after the administration, we repeated laboratory tests, ECG, vital signs/weight measurements,
physical examinations, pain VAS, K-WOMAC, and patient global assessment. The efficacy
and safety of the treatment drug was assessed at weeks 0, 2, and 4. The primary outcome
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variable was the change in 100 mm pain VAS at week 4 as compared to the baseline. Secondary
efficacy variables were the change in 100 mm pain VAS between week 2 and baseline,
K-WOMAC score change between baseline and weeks 2 or 4, patient global assessment at
weeks 2 and 4. The frequency and amount of rescue medicine usage at weeks 0, 2 and 4 were
also assessed as the secondary outcome variable. We checked whether the drug administration
was properly performed and the amount of the rescue medicine consumption at every visit.
Global patient assessment was performed using a 5-point Likert-type scale regarding effective-
ness of the medicine used (where 5 = excellent, 1 = very poor). Patients who rated their condi-
tion as excellent and good were categorized as the efficacy group. In addition, for safety
analysis, adverse events, clinical laboratory tests, vital signs, and physical examination results
were assessed. The AEs were categorized into the serious AEs, the drug-related AEs, and the
discontinuation because of AEs.
Statistical analyses
The data obtained from the subjects of the clinical trial were analyzed in three forms: safety set,
full analysis (FA) set, and per protocol (PP) set. The safety set included all data from the
patients who received at least one drug for the clinical trial. The FA set included all patients for
whom the data on primary efficacy evaluation parameters were obtained after the administra-
tion of the drugs for the clinical trial among the participants who received the drugs for the
clinical trial at least once. The PP set included data from the patients who had completed the
drug administration in accordance with the protocol among the participants included in the
FA set.
All the statistical significance tests were carried out by the two-sided test at a significance
level (α) of 5%, and non-inferiority was tested using confidence interval. In the analysis of the
demographic data and baseline characteristics data, continuous data were analyzed by inde-
pendent t–test, while categorical data were analyzed by Chi-square test or Fisher’s exact test.
We assumed that pelubiprofen met the non-inferiority criterion if the upper limit of the one-
sided 97.5% confidence interval for the difference in terms of pain VAS was below 15 mm
(average changes of pain VAS in the pelubiprofen group-pain VAS reduction in the aceclofe-
nac group). Additionally, a sensitivity analysis was performed using ANCOVA with factors of
treatment group, site as a covariate for evaluating the treatment by center interaction. The dif-
ferences in the K-WOMAC scale changes between clinical visits were determined using paired
t-test. The results of global patient assessment were analyzed using Chi-square test or Fisher’s
exact test. For the use frequency of the rescue medicine, Chi-square test or Fisher’s exact test
and independent t-test were used for analysis. For safety confirmation, Chi-square test or Fish-
er’s exact test was used to analyze the difference of the rate of adverse events. Laboratory tests,
vital signs, and physical examination results were analyzed using paired t-test or Wilcoxon
signed rank test.
Results
Patient characteristics
A total of 191 patients who received the study medication at least once were randomized in the
10 centers (Fig 1). Among these, 4 patients withdrew their consent before taking the study
drug. Therefore, we analyzed the safety set with the remaining 187 patients. The FA set con-
sisted of all 181 patients for whom the data on primary efficacy variable were obtained before 6
patients (n = 2 in the pelubiprofen group and n = 4 in the aceclofenac group) withdrew their
consent. The PP set (n = 155) excluded 19 patients with serious protocol violations (n = 9 in
the pelubiprofen group and n = 10 in the aceclofenac group) or those who withdrew during
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the study period (n = 3 in the pelubiprofen group and n = 4 in the aceclofenac group). Serious
protocol violations included inadequate inclusion/exclusion criteria (n = 6), taking the con-
comitant medication during the study period (n = 9), low adherence rate of taking study drugs
below 70% (n = 4), and out of window period visits (n = 1), for duplicate counting.
The study population was predominantly female (73.3% {140 of 191 patients}) with the
mean age of 62.1 years (standard deviation {SD}, 7.5 years; range, 43–77 years in the pelubipro-
fen group and 48–79 years in the aceclofenac group). Mean duration of knee OA was 3.2 years.
The baseline characteristics were well balanced between the groups for the patients’ age, gen-
der, laterality, K-L grade. The most common comorbidities were hypertension in both groups
(Table 1).
Primary efficacy outcome
In the PP population, the 100 mm pain VAS score of the pelubiprofen group was 57.9 mm at
week 0 and 35.9 mm at week 4. The mean change in pain VAS scores was −22.0 mm between
weeks 0 and 4. In the aceclofenac group, 100 mm pain VAS score was 56.3 mm at week 0 and
34.4 mm at week 4. The mean change in pain VAS score was −21.9 mm between weeks 0 and 4
(Fig 2, Table 2). The difference of pain VAS changes between pelubiprofen group and aceclofe-
nac group was -0.05 and the one sided 97.5% confidence interval (-4.56, 6.25) of the change
difference met the criteria for non-inferiority. The FA population showed similar results to
those of the PP population. (Table 2). The one-sided 97.5% confidence interval (-3.76, 6.64) of
the change difference also met the criteria for non-inferiority. Additionally, there was no statis-
tically significant interaction between the covariate and factor (treatment group, site.) (PP:
p = 0.3625, FA: p = 0.3552) (Table 3).
Secondary efficacy outcome
The change of the 100-mm pain VAS score from weeks 0 to 2 did not differ between the
two groups (PP population, p = 0.410 and FA population, p = 0.253, respectively), and the
one-sided 95% confidence interval (PP population, -2.76, 6.73 and FA population, -1.81,
6.81, respectively) of the change difference met the criteria for non-inferiority. In the
change of K-WOMAC scores, no difference in any part and within any study period was
Fig 1. Flow chart of patient disposition.
https://doi.org/10.1371/journal.pone.0238024.g001
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observed in both PP and FA sets (Tables 4 and 5). In terms of patient global assessment
and use of rescue medicine, there was no difference between the two groups in both PP
and FA sets (Table 6).
Safety analysis
Forty-nine cases of AEs were reported from 35 patients (18.3%). Eleven AEs were reported
from 10 patients (10.6%) in the pelubiprofen group, and 38 AEs were reported from 25
patients (26.9%) of the aceclofenac group. Among the 26 drug-related AEs, GI problems were
the most frequent (14 cases in total; 7 cases of dyspepsia). The pelubiprofen group had a signif-
icantly reduced rate of drug-related AEs compared to the aceclofenac group (p = 0.011).
Among the drug-related AEs, the pelubiprofen group showed a significantly lower rate of GI
AEs than that in the aceclofenac group (3% vs 11%, p = 0.048) (Table 7).
Discussion
NSAIDs are the most commonly used medications for pain reduction and function
improvement in the patients with symptomatic knee OA. Both safety and efficacy of
NSAIDs are essential, as most patients with knee OA use the NSAIDs in the long term. In
the present study, we sought to evaluate non-inferiority of short-term use of pelubiprofen
CR to aceclofenac regarding clinical efficacy and rate of AEs in the highly selected sample of
patients with symptomatic knee OA. The principal findings of this study were that non-
inferiority of the pelubiprofen CR to aceclofenac was confirmed in terms of 100 mm pain
VAS, K-WOMAC, and global patient assessment after a 4-week course of medication with a
reduced rate of drug-related AEs.
Table 1. Demographic and baseline patient characteristics.
Parameters Treatment groups
Pelubiprofen (n = 95) Aceclofenac (n = 96)
Age (years)� 62.1 ± 7.8 62.1 ± 7.2
Sex, no. (%)
Female 74 (78) 66 (69)
Male 21 (22) 30 (31)
Duration of OA (years)� 3.7 ± 4.0 2.7 ± 3.2
Laterality
Right 52 (55) 53 (55)
Left 43 (45) 43 (45)
K-L grade
Grade I 12 (13) 8 (8)
Grade II 40 (42) 53 (55)
Grade III 43 (45) 35 (37)
Comorbidities
Hypertension 32 (34) 36 (38)
Chronic gastritis 1 (1) 2 (2)
Diabetes mellitus 12 (13) 13 (13)
Osteoporosis 5 (5) 5 (5)
Data are presented with number and percent in parenthesis.
� Data are presented with means and standard deviations. (mean ± standard deviation)
https://doi.org/10.1371/journal.pone.0238024.t001
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Fig 2. Efficacy outcome: Analysis of 100-mm pain VAS. A. Efficacy outcome: analysis of 100-mm pain VAS at week 2, 4 _ change of
100mm Pain VAS (PP). B. Efficacy outcome: analysis of 100-mm pain VAS at week 2, 4 _ change of 100mm Pain VAS (FA).
https://doi.org/10.1371/journal.pone.0238024.g002
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The efficacy of traditional pelubiprofen 90 mg has been reported to be non-inferior to other
control NSAIDs. Shin et al. compared traditional pelubiprofen 90 mg (30 mg three times
daily) to aceclofenac 200 mg (100 mg twice daily) in the patients with lower back pain [11].
The authors reported that the mean changes in 100 mm pain VAS score of 4-week treatment
were -30.0 ± 19.85 mm and -28.88 ± 17.86 mm in the pelubiprofen group and the aceclofe-
nac group, respectively. Furthermore, in a 6-week, multicenter, randomized, double-blind
study, Choi et al. compared the efficacy of the traditional pelubiprofen 90 mg with celecoxib
200 mg in the patients with RA. The results of this study showed that the pelubiprofen was
non-inferior to celecoxib with a decrease in VAS pain severity (difference, 5.0 ± 20.1) [9].
The results of the present study are similar to previous reports in terms of clinical efficacy
when comparing the CR form of pelubiprofen 90 mg and aceclofenac 200 mg in the patients
with symptomatic knee OA. Therefore, our findings are largely consistent with previous
research in this area.
However, despite confirming the reduced GI AEs rate of pelubiprofen CR as compared
to aceclofenac in the present study, the rate of GI AEs in pelubiprofen remains a controver-
sial issue. In a previous study in the patients with low back pain, the rate of heartburn and
Table 2. Primary efficacy outcome: Analysis of 100-mm pain VAS at week 4 (PP and FA sets).
Parameters Treatment groups Difference
Pelubiprofen 90 mg Aceclofenac 200mg Mean One-sided 97.5% CI
PP set (Pelubiprofen [n = 80], Aceclofenac [n = 75])
Week 0� 57.9 ± 11.9 56.3 ± 11.9
Week 4� 35.9 ± 18.8 34.4 ± 16.5
Differences (week 0 between week 4)� -22.0 ± 18.1 -21.9 ± 18.3 -0.02 -4.56, 6.25
FA set (Pelubiprofen [n = 92], Aceclofenac [n = 89])
Week 0� 57.5 ± 11.9 56.6 ± 11.8
Week 4� 36.7 ± 19.0 34.9 ± 17.4
Differences (week 0 between week 4)� -20.8 ± 18.3 -21.7 ± 19.7 0.89 -3.76, 6.64
� Data are presented with means and standard deviations. (mean ± standard deviation) Abbreviations = PP, per protocol; FA, full analysis; CI, confidence interval
Adjusted by treatment group
Covariate: baseline mean of 100mm Pain VAS
https://doi.org/10.1371/journal.pone.0238024.t002
Table 3. Primary efficacy outcome: analysis (adding site factor) of 100-mm pain VAS at week 4 (PP and FA sets).
Parameters Treatment groups Difference
Pelubiprofen 90 mg Aceclofenac 200mg Mean one-sided 97.5% CI
PP set (Pelubiprofen [n = 80], Aceclofenac [n = 75])
Week 0� 57.9 ± 11.9 56.3 ± 11.9
Week 4� 35.9 ± 18.8 34.4 ± 16.5
Differences (week 0 between week 4)� -22.0 ± 18.1 -21.9 ± 18.3 -0.02 -4.72, 5.51
FA set (Pelubiprofen [n = 92], Aceclofenac [n = 89])
Week 0� 57.5 ± 11.9 56.6 ± 11.8
Week 4� 36.7 ± 19.0 34.9 ± 17.4
Differences (week 0 between week 4)� -20.8 ± 18.3 -21.7 ± 19.7 0.89 -3.89, 6.02
� Data are presented with means and standard deviations. (mean ± standard deviation) Abbreviations = PP, per protocol; FA, full analysis; CI, confidence interval
Adjusted by treatment group, site
Covariate: baseline mean of 100mm Pain VAS
https://doi.org/10.1371/journal.pone.0238024.t003
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abdominal discomfort were similar between the pelubiprofen and aceclofenac groups [11].
However, in the study that compared the rate of AEs between pelubiprofen and celecoxib in
RA patients, 50.6% reported 62 AEs in the pelubiprofen group, whereas 36.8% reported 33
AEs in the celecoxib group (p = 0.09). These findings suggest that further research is needed
to confirm the GI safety of the pelubiprofen to treat OA. On the other hand, the CR form of
a drug may reduce local gastrointestinal irritation caused by rapid localized dissolution of
the traditional form of the drug. However, in a previous study that compared aceclofenac
controlled release (CR) (200 mg once daily) to a traditional twice daily aceclofenac dose
(100 mg twice daily), the patients with aceclofenac CR showed a higher rate of heartburn
(10 of 45 vs. 3 of 45) even when there was no difference in terms of overall GI complications
between the two groups [16]. The authors attributed the increased rate of heartburn in ace-
clofenac CR group to the fact that a single daily dose might cause a greater acidic insult to
gastric mucosa [16]. In contrast, in the present study, the pelubiprofen CR group showed
reduced GI AEs than the aceclofenac group. We were unable to fully explain these contra-
dictory findings; however, given that there was no difference in the GI complication rate
between traditional pelubiprofen and aceclofenac in a previous study [11], the CR form of
pelubiprofen might have improved gastroprotective effects as compared to the traditional
form of pelubiprofen. In a pelubiprofen CR tablet, crumbling is progressed from the surface
of the drug, resulting in a slow release through the micropores. In addition, it was reported
Table 4. Analyses of secondary efficacy outcomes (PP set): 100-mm pain VAS at week 2 and K-WOMAC scores.
Parameters Treatment groups Difference
Pelubiprofen 90 mg Aceclofenac 200mg Mean 95% CI
100-mm pain VAS
Week 0� 57.9±11.9 56.3±11.9
Week 2� 41.2±15.7 38.4±16.3
Differences (week 0 between week 2)� -16.7±14.7 -17.9±17.2 1.22 -2.76, 6.73
K-WOMAC pain
Week 0 8.1 7.8
Week 2 6.0 5.0
Week 4 5.9 4.7
Differences (week 0 between week 2)� -2.1±3.1 -2.8±2.6 0.7 -0.17, 1.64
Differences (week 0 between week 4)� -2.2±3.7 -3.1±3.3 0.9 -0.22, 2.03
K-WOMAC stiffness
Week 0 3.9 3.7
Week 2 2.9 2.5
Week 4 2.7 2.4
Differences (week 0 between week 2)� -1.0±1.5 -1.2±1.4 0.14 -0.33, 0.60
Differences (week 0 between week 4)� -1.2±1.4 -1.3±1.6 0.07 -0.40, 0.54
K-WOMAC function
Week 0 29.5 28.8
Week 2 22.8 20.7
Week 4 21.2 18.6
Differences (week 0 between week 2)� -6.7±11.2 -8.1±8.8 1.38 -1.80, 4.56
Differences (week 0 between week 4)� -8.3±12.3 -10.2±10.5 1.87 -1.77, 5.52
� Data are presented with means and standard deviations. (mean ± standard deviation) The statistical analyses were performed using analysis of covariance (ANCOVA)
test. Abbreviations: PP, per protocol; VAS, visual analogue scale; CI, confidence interval
https://doi.org/10.1371/journal.pone.0238024.t004
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that pelubiprofen CR rarely dissolves in an environment where the pH is 1.2 [17]. There-
fore, pelubiprofen CR tablets can hardly be diluted in the stomach for 2 hours, which could
reduce gastric mucosal irritation. There were significant differences only in minor GI disor-
ders, including dyspepsia among AE of pelubiprofen and aceclofenac in this study. In previ-
ous studies, traditional NSAIDs increases the risk of severe GI side effects by three to four
times. [18] In the short term, even this minor problem may cause more severe side effects
when taken for a long time.
The present study has several limitations. First, as we mentioned above, most patients with
symptomatic knee OA use NSAIDs in the long term. However, in the present study, the drugs
were prescribed only for 4 weeks. In general, NSAIDs are often taken for a long time in
patients with arthritis, so a long period of study is needed. Therefore, in further research, it is
necessary to evaluate the efficacy and safety of the pelubiprofen CR in the long-term period.
Second, in our study, the patients with a higher risk of cardiovascular AEs were excluded.
Therefore, we did not determine the safety of the pelubiprofen CR in the patients with
increased cardiovascular risk. So studies on the cardiovascular risk of pelubiprofen and its use
in patients with high cardiovascular risk are needed. Furthermore, since this study excluded
patients with cardiovascular disease as well as many other serious diseases, there is a limitation
that this study was conducted only for otherwise healthy patients. So patients with severe dis-
ease, as well as cardiovascular disease, included in the exclusion criteria of this study will need
Table 5. Analyses of secondary efficacy outcomes (FA set): 100-mm pain VAS at week 2 and K-WOMAC scores.
Parameters Treatment groups Difference
Pelubiprofen 90 mg Aceclofenac 200mg Mean 95% CI
100-mm pain VAS
Week 0� 57.5±11.9 56.6±11.8
Week 2� 41.7±15.6 38.8±15.5
Differences (week 0 between week 2)� -15.9±14.9 -17.9±16.8 1.95 -1.81, 6.81
K-WOMAC pain
Week 0 8.0 7.7
Week 2 6.1 5.1
Week 4 6.0 4.8
Differences (week 0 between week 2)� -1.9±3.0 -2.7±2.5 0.75 -0.08, 1.57
Differences (week 0 between week 4)� -2.0±3.6 -3.0±3.3 0.94 -0.08, 1.97
K-WOMAC stiffness
Week 0 3.8 3.6
Week 2 2.9 2.5
Week 4 2.7 2.5
Differences (week 0 between week 2)� -1.0±1.6 -1.1±1.4 0.10 -0.35, 0.55
Differences (week 0 between week 4)� -1.1±1.6 -1.1±1.6 0.04 -0.43, 0.50
K-WOMAC function
Week 0 29.0 28.6
Week 2 23.1 20.7
Week 4 21.4 19.0
Differences (week 0 between week 2)� -6.1±11.6 -7.8±8.6 1.63 -1.37, 4.62
Differences (week 0 between week 4)� -7.6±12.7 -9.7±10.8 2.10 -1.37, 5.56
� Data are presented with means and standard deviations. (mean ± standard deviation) The statistical analyses were performed using analysis of covariance (ANCOVA)
test. Abbreviations: FA, full analysis; VAS, visual analogue scale; CI, confidence interval
https://doi.org/10.1371/journal.pone.0238024.t005
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further long term studies, too. Third, the criterion for non-inferiority was rather large. How-
ever, the mean difference of 100 mm pain VAS between the pelubiprofen group and the ace-
clofenac group in the PP set analysis was only 0.02 (one sided 97.5% confidence interval, -4.56,
6.25). Therefore, the same outcome could have been achieved in terms of 100 mm pain VAS,
although a stricter criterion was used.
In conclusion, the results of this clinical trial demonstrated that, in the patients with symp-
tomatic knee OA, pelubiprofen CR 90 mg tablet was not inferior to aceclofenac 200 mg in
terms of efficacy and number of adverse events.
Table 6. Secondary efficacy outcomes: patient global assessment and use of rescue medicine (PP and FA sets).
Parameters Treatment groups p value
Pelubiprofen 90 mg Aceclofenac 200mg
PP set (Pelubiprofen [n = 80], Aceclofenac [n = 75])
Patient global assessment
Week 2
Efficacy n (%) 61(76.3) 62(82.7) 0.626†
Non-efficacy n (%) 19(23.7) 13(17.3)
Week 4
Efficacy n (%) 57(71.3) 55(73.3) 0.772†
Non-efficacy n (%) 23(28.7) 20(26.7)
Frequency1 of rescue medicine
Week 0� 4.2±2.9 4.7±3.9 0.884�
Week 2� 4.1±3.0 4.2±3.0 0.914�
Week 4� 3.9±2.9 4.3±3.2 0.673�
Total dose2 of rescue medicine
Week 0� 26.0±27.6 44.0±81.8 1.000�
Week 2� 25.6±30.8 25.8±33.0 0.849�
Week 4� 23.6±29.9 29.1±35.1 0.613�
FA set (Pelubiprofen [n = 92], Aceclofenac [n = 89])
Patient global assessment
Week 2
Efficacy 66(72.5) 71(80.7) 0.198†
Non-efficacy 25(27.5) 17(19.3)
Week 4
Efficacy 62(67.4) 65(73.0) 0.407†
Non-efficacy 30(32.6) 24(27.0)
Frequency1 of rescue medicine
Week 0� 4.6±3.5 5.1±4.1 0.712�
Week 2� 4.6±3.2 4.1±2.9 0.583�
Week 4� 4.1±2.9 4.7±3.3 0.575�
Total dose2 of rescue medicine
Week 0� 33.5±44.1 54.2±84.8 0.884�
Week 2� 31.0±35.5 24.9±31.2 0.623�
Week 4� 25.5±30.7 33.0±36.0 0.542�
� Data are presented with means and standard deviations. (mean ± standard deviation) 1Number of doses 2Total number of tablets
†Chi-square test, �Wilcoxon’s rank sum test. Abbreviations: PP, per protocol; FA, full analysis; CI, confidence interval
https://doi.org/10.1371/journal.pone.0238024.t006
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